Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Compendia and Althea develop breast cancer assay as companion Dx platform
January 2011
SHARING OPTIONS:

ANN ARBOR, Mich.Compendia Bioscience and Althea Diagnostics recently announced that they will develop a product and service offering called the Breast Cancer Segregation Panel as a platform for companion diagnostic development. The panel measures 96 genes that represent key molecular variability of breast cancer and have been derived from a proprietary meta-analysis of cancer genomic profiles from more than 5,000 clinical samples. The assay has been optimized by Althea to measure the genes using quantitative RT-PCR from formalin-fixed tissue (FFPE) samples to enable rapid translation to real-world clinical settings. Compendia will analyze the data generated by the assay and perform correlation studies to end-points of interest such as drug response, allowing for development of multiple drug-specific companion diagnostics from a standardized platform. The companies also plan to develop similar assays for other cancer disease types.    

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.